Does This Patient Have a Severe Snake Envenomation?: The Rational Clinical Examination Systematic Review
- PMID: 30758508
- DOI: 10.1001/jamasurg.2018.5069
Does This Patient Have a Severe Snake Envenomation?: The Rational Clinical Examination Systematic Review
Abstract
Importance: Venomous snakebite severity ranges from an asymptomatic dry bite to severe envenomation and death. The clinical evaluation aids in prognosis and is essential to determine the risks and potential benefits of antivenom treatment.
Objectives: To identify historical features, clinical examination findings, basic laboratory testing, and clinical grading scales that will risk-stratify patients with pit viper snake envenomation for severe systemic envenomation, severe tissue injury, and/or severe hematologic venom effects.
Data sources: We conducted a structured search of PubMed (1966-October 3, 2017) and Embase database (1980-October 3, 2017) to identify English-language studies that evaluated clinical features predictive of severe envenomation.
Study selection: We included studies that evaluated the test performance of at least 1 clinical finding with an acceptable reference standard of severe envenomation for venomous snakes of the Western Hemisphere. Only studies involving the most common subfamily, Crotalinae (pit vipers), were evaluated. Seventeen studies with data were available for abstraction.
Data extraction and synthesis: The clinical features assessed and severity outcome measures were extracted from each original study. We assessed severity in 3 categories: systemic toxicity, tissue injury, and hematologic effects. Differences were resolved by author consensus.
Results: The pooled prevalence of severe systemic envenomation was 14% (95% CI, 9%-21%). The pooled prevalence of severe tissue injury and severe hematologic venom effects were 14% (95% CI, 12%-16%) and 18% (95% CI, 8%-27%), respectively. Factors increasing the likelihood of severe systemic envenomation included the time from bite to care of 6 or more hours (likelihood ratio [LR], 3.4 [95% CI, 1.1-6.4]), a patient younger than 12 years (LRs, 3.2 [95% CI, 1.5-7.1] and 2.9 [95% CI, 1.3-6.2]), large snake size (LR, 3.1 [95% CI, 1.5-5.7]), and ptosis (LRs, 1.4 [95% CI, 1.0-2.1] and 3.8 [95% CI, 1.8-8.3]). Envenomation by the genus Agkistrodon (copperhead and cottonmouth), as opposed to rattlesnakes, decreased the likelihood of severe systemic envenomation (LR, 0.28 [95% CI, 0.10-0.78]). Initial hypofibrinogenemia (LR, 5.1 [95% CI, 1.7-15.0]) and thrombocytopenia (LR, 3.7 [95% CI, 1.9-7.3]) increased the likelihood of severe hematologic venom effects. Other clinical features from history, physical examination, or normal laboratory values were not discriminative.
Conclusions: Clinical features can identify patients at increased risk of severe systemic envenomation and severe hematologic venom effects, but there are few features that are associated with severe tissue injury or can confidently exclude severe envenomation. Physicians should monitor patients closely and be wary of progression from nonsevere to a severe envenomation and have a low threshold to escalate therapy as needed.
Comment in
-
What History, Examination, and Laboratory Findings Suggest Severe Snake Envenomation?Ann Emerg Med. 2019 Sep;74(3):450-452. doi: 10.1016/j.annemergmed.2019.04.034. Epub 2019 Jul 31. Ann Emerg Med. 2019. PMID: 31377011 No abstract available.
Similar articles
-
Cottonmouth snake bites reported to the ToxIC North American snakebite registry 2013-2017.Clin Toxicol (Phila). 2020 Mar;58(3):178-182. doi: 10.1080/15563650.2019.1627367. Epub 2019 Jun 13. Clin Toxicol (Phila). 2020. PMID: 31190571
-
Prevalence of hematologic toxicity from copperhead envenomation: an observational study.Clin Toxicol (Phila). 2020 Apr;58(4):262-265. doi: 10.1080/15563650.2019.1644346. Epub 2019 Jul 25. Clin Toxicol (Phila). 2020. PMID: 31342795
-
Clinically Significant Envenomation From Postmortem Copperhead (Agkistrodon contortrix).Wilderness Environ Med. 2017 Mar;28(1):43-45. doi: 10.1016/j.wem.2016.09.007. Epub 2016 Nov 18. Wilderness Environ Med. 2017. PMID: 27876196
-
Snake bite: pit vipers.Clin Tech Small Anim Pract. 2006 Nov;21(4):174-82. doi: 10.1053/j.ctsap.2006.10.008. Clin Tech Small Anim Pract. 2006. PMID: 17265901 Review.
-
Management of venomous snakebite injury to the extremities.J Am Acad Orthop Surg. 2010 Dec;18(12):749-59. doi: 10.5435/00124635-201012000-00005. J Am Acad Orthop Surg. 2010. PMID: 21119141 Review.
Cited by
-
Oral varespladib for the treatment of snakebite envenoming in India and the USA (BRAVO): a phase II randomised clinical trial.BMJ Glob Health. 2024 Oct 22;9(10):e015985. doi: 10.1136/bmjgh-2024-015985. BMJ Glob Health. 2024. PMID: 39442939 Free PMC article. Clinical Trial.
-
Capacity of community health centers to treat snakebite envenoming in indigenous territories of the Brazilian Amazon.Toxicon. 2024 Apr;241:107681. doi: 10.1016/j.toxicon.2024.107681. Epub 2024 Mar 10. Toxicon. 2024. PMID: 38461896
-
Clinical Risk Factors Associated with Poor Outcomes in Snake Envenoming: A Narrative Review.Toxins (Basel). 2023 Nov 28;15(12):675. doi: 10.3390/toxins15120675. Toxins (Basel). 2023. PMID: 38133179 Free PMC article. Review.
-
Photobiomodulation Therapy to Treat Snakebites Caused by Bothrops atrox: A Randomized Clinical Trial.JAMA Intern Med. 2024 Jan 1;184(1):70-80. doi: 10.1001/jamainternmed.2023.6538. JAMA Intern Med. 2024. PMID: 38048090 Free PMC article. Clinical Trial.
-
Cold Finger: Raynaud Phenomenon Following Snakebite Envenoming by Nikolsky's Viper (Vipera berus nikolskii).Toxins (Basel). 2023 Oct 4;15(10):598. doi: 10.3390/toxins15100598. Toxins (Basel). 2023. PMID: 37888629 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
